REG - GSK PLC - Statement: Zantac Litigation Update BC Canada

GSKAnnouncement

12/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230512:nRSL1827Za&default-theme=true

RNS Number : 1827Z  GSK PLC  12 May 2023

Issued: 12 May 2023, London UK

 

Statement: Zantac (ranitidine) litigation

 

 

GSK plc (LSE/NYSE: GSK) welcomes the decision of the British Columbia Supreme
Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795, dismissing a proposed
class action on behalf of a class of ranitidine users in Canada.

 

Since 2019 there have been 13 peer-reviewed epidemiological studies conducted
looking at human data regarding the use of ranitidine. The decision recognises
that after more than three years of extensive study, the scientific consensus
is that there is no consistent or reliable evidence that ranitidine increases
the risk for any type of cancer.

 

The Court stated: "Given the uncontroverted evidence that neither ranitidine
nor NDMA are reliably associated with increased cancer risk, and the absence
of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has
failed to raise a bona fide triable issue regarding injury due to the
ingestion and/or purchase of ranitidine."

 

GSK will continue to vigorously defend proposed class actions by ranitidine
users that have been filed in Ontario and Quebec as well as individual actions
filed by ranitidine users in Canada.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q1 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKDBQNBKBAPD